F. Raal

发表

Gestational trophoblastic neoplasia and disorders of thyroid function

G. Teckie, A. M. Klisiewicz, F. Raal, 2008 .

A randomized clinical trial comparing metabolic parameters after 48 weeks of standard‐ and low‐dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV‐infected South African patients

F. Raal, I. Sanne, M. Rassool, 2014, HIV medicine.

Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials.

L. G. Conde, Ulf Landmesser, Lawrence A. Leiter, 2023, Atherosclerosis.

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.

S. Humphries, S. Yamashita, G. Watts, 2016, The lancet. Diabetes & endocrinology.

Recent origin and spread of a common Lithuanian mutation, G197del LDLR, causing familial hypercholesterolemia: positive selection is not always necessary to account for disease incidence among Ashkenazi Jews.

Y. Friedlander, V. Meiner, F. Raal, 2001, American journal of human genetics.

A consensus statement from the European Atherosclerosis Society Consensus Panel

B. Sluis, A. Catapano, B. Ference, 2018 .

Low-density lipoproteins cause atherosclerotic cardiovascular disease.1. Evidence from genetic, epidemiologic, and clinical studies

B. Sluis, A. Catapano, B. Ference, 2018 .

Evidence from A from

B. Sluis, A. Catapano, B. Ference, 2017 .

Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia.

F. Raal, B. Joffe, M. Veller, 1999, The American journal of cardiology.

Cerebrotendinous xanthomatosis without neurological involvement

M. van der Graaf, L. Kluijtmans, R. Wevers, 2021, Journal of internal medicine.

Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy

C. Town, F. Raal, D. Blom, 2011, Circulation.

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).

J. Car, E. Mirrakhimov, A. Sahebkar, 2018, Atherosclerosis.

Familial hypercholesterolaemia: A global call to arms.

J. Car, A. Sahebkar, G. Latkovskis, 2015, Atherosclerosis.

Review the Polygenic Nature of Hypertriglyceridaemia: Implications for Defi Nition, Diagnosis, and Management

J. Borén, S. Humphries, M. Taskinen, 2022 .

[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society].

P. Pajukanta, A. Tybjaerg-hansen, J. Kuivenhoven, 2015, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects.

D. Rubinsztein, F. Raal, G. Utermann, 1997, Atherosclerosis.

Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.

T. Heinonen, J. Lovalvo, Ellen Klepack, 2003, Atherosclerosis.

Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention.

L. G. Conde, Ulf Landmesser, R. S. Wright, 2024, Atherosclerosis.

The implementation of guidelines in a South African population with type 2 diabetes

N. Butkow, Y. Pinchevsky, T. Chirwa, 2013 .

Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

N. Antonio-Villa, A. Vargas-Vázquez, J. Jozwiak, 2023, The Lancet.

Lipoprotein(a) in homozygous familial hypercholesterolemia.

F. Raal, G. Utermann, A. Lingenhel, 2000, Arteriosclerosis, thrombosis, and vascular biology.